Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antihypertensive Outcomes Labeling Emphasized By FDA After ALLHAT

Executive Summary

FDA is planning to include clinical outcomes data in antihypertensive labeling in light of findings from the ALLHAT and LIFE studies

You may also be interested in...



Amgen Head-To-Head R&D Strategy Speaks To Growing Importance Of Payers

Amgen's strategy of conducting head-to-head trials of its products against current standards of care pre-approval indicates the firm is focusing on effectively positioning products in an increasingly competitive, Medicare-oriented reimbursement environment

Amgen Head-To-Head R&D Strategy Speaks To Growing Importance Of Payers

Amgen's strategy of conducting head-to-head trials of its products against current standards of care pre-approval indicates the firm is focusing on effectively positioning products in an increasingly competitive, Medicare-oriented reimbursement environment

Meta-Analysis In Lancet Projects End of Beta-Blockers For Hypertension

Beta-blockers should not remain the first-line therapy for high blood pressure, researchers of a study published in the Oct. 18 Lancet said

Related Content

UsernamePublicRestriction

Register

LL1135972

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel